The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
On December 22, 2025, the U.S. Food and Drug Administration
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
As the GLP-1 gold rush enters its most aggressive phase,
Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
In a strategic move poised to reshape the landscape of
AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
AbbVie, a leading biopharmaceutical company, has taken a significant step
MOST POPULAR
